[b]Alzther Industries (ISIN: KR7119857621)[/b] a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease, today announced that it has conducted a series of tests in order to perfect a procedure that it will be able to diagnose blood test for early stage breast cancer.
The test works by detecting gene expression patterns (2) in peripheral blood – i.e.: a normal venous sample - not taken from the breast. A blood test will give women the opportunity to detect breast cancer at its earliest stages – when usually undetectable by touch or mammograms - and when they have no symptoms.
The blood test has been validated in international trials, most recently in India, suggesting there is no ethnic variability in the gene expression signature.
“I think it is really important to investigate better ways of detecting early breast cancer in young women. All health professionals who work with breast cancer are concerned that mammograms may be sub-optimal in young women under 47. Therefore, a new test used alongside mammography would provide the optimal chance of detecting the cancer as early as possible.” said Choi Kyong-Duk, M.D., Scientific Advisory Board.
Dr. Sung Hwan-Kuk, Chief Executive Officer of Alzther Industries, adds: “The Alzther Industries breast cancer blood test is an exciting new weapon in the fight against breast cancer. By using the test and mammography together we may be able to detect tumors at an early stage. The test analyses the expression of genes which are not specifically cancer genes. By studying these non-cancer genes, experts can detect a specific, distinctive gene expression pattern. This is breast cancer's unique fingerprint, in blood.”

[b]About Alzther Industries (ISIN: KR7119857621) [/b]

Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.